BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:MariTide (maridebart cafraglutide) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of MariTide (maridebart cafraglutide)\, from
  ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06858878-143@assetmemo.bio
DTSTAMP:20261121T005422Z
DTSTART;VALUE=DATE:20270121
DTEND;VALUE=DATE:20270122
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT068588
 78)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With
  Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight\nEstimated pr
 imary completion: 21 January 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/maridebart-cafraglutide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06858878
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06858839-143@assetmemo.bio
DTSTAMP:20261121T005422Z
DTSTART;VALUE=DATE:20270121
DTEND;VALUE=DATE:20270122
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT068588
 39)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 
 2 Diabetes Mellitus Who Have Obesity or Are Overweight\nEstimated primary 
 completion: 21 January 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/maridebart-cafraglutide#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06858839
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07832799-143@assetmemo.bio
DTSTAMP:20261121T005422Z
DTSTART;VALUE=DATE:20270323
DTEND;VALUE=DATE:20270324
SUMMARY:MariTide (maridebart cafraglutide): Phase 1 readout est. (NCT078327
 99)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 1\, Obesity.\nStudy:
  Comparing the Extent to Which Two Maridebart Cafraglutide Drug Products A
 re Made Available in the Body After a Single Subcutaneous Dose\nEstimated 
 primary completion: 23 March 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/maridebart-cafraglutide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07832799
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06987695-143@assetmemo.bio
DTSTAMP:20261121T005422Z
DTSTART;VALUE=DATE:20270427
DTEND;VALUE=DATE:20270428
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT069876
 95)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in J
 apan Who Have Obesity Disease\nEstimated primary completion: 27 April 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/maridebart-cafraglu
 tide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06987695
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07871409-143@assetmemo.bio
DTSTAMP:20261121T005422Z
DTSTART;VALUE=DATE:20270616
DTEND;VALUE=DATE:20270617
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT078714
 09)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Home Self-administration of Maridebart Cafraglutide With Autoinjector in 
 Adults Living With Obesity or Overweight\nEstimated primary completion: 16
  June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/maridebar
 t-cafraglutide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07871409
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07921316-143@assetmemo.bio
DTSTAMP:20261121T005422Z
DTSTART;VALUE=DATE:20270726
DTEND;VALUE=DATE:20270727
SUMMARY:MariTide (maridebart cafraglutide): Phase 1 readout est. (NCT079213
 16)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 1\, Obesity.\nStudy:
  Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made A
 vailable in the Body When Administered Using Two Subcutaneous Presentation
 s After Multiple Doses\nEstimated primary completion: 26 July 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/maridebart-cafraglutide#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0792131
 6
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225686-143@assetmemo.bio
DTSTAMP:20261121T005422Z
DTSTART;VALUE=DATE:20270820
DTEND;VALUE=DATE:20270821
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT072256
 86)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstruc
 tive Sleep Apnea on Positive Airway Pressure Therapy\nEstimated primary co
 mpletion: 20 August 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/maridebart-cafraglutide#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07225686
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07441252-143@assetmemo.bio
DTSTAMP:20261121T005422Z
DTSTART;VALUE=DATE:20270825
DTEND;VALUE=DATE:20270826
SUMMARY:MariTide (maridebart cafraglutide): Phase 2 readout est. (NCT074412
 52)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 2\, Obesity.\nStudy:
  A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adu
 lts Living With Elevated Liver Fat and Obesity or Overweight\nEstimated pr
 imary completion: 25 August 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/maridebart-cafraglutide#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07441252
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07226765-143@assetmemo.bio
DTSTAMP:20261121T005422Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT072267
 65)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3.\nStudy: Maridebar
 t Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep
  Apnea Not on Positive Airway Pressure (PAP) Therapy\nEstimated primary co
 mpletion: 30 August 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/maridebart-cafraglutide#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07226765
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07908316-143@assetmemo.bio
DTSTAMP:20261121T005422Z
DTSTART;VALUE=DATE:20271220
DTEND;VALUE=DATE:20271221
SUMMARY:MariTide (maridebart cafraglutide): Phase 1 readout est. (NCT079083
 16)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 1\, Obesity.\nStudy:
  Comparing the Extent to Which Maridebart Cafraglutide is Made Available i
 n the Body of Participants Living With Overweight or Obesity After Switchi
 ng From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)\nEstimated pri
 mary completion: 20 December 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/maridebart-cafraglutide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07908316
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684144-143@assetmemo.bio
DTSTAMP:20261121T005422Z
DTSTART;VALUE=DATE:20271226
DTEND;VALUE=DATE:20271227
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT076841
 44)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Extension Trial to Evaluate the Long-term Efficacy\, Safety\, and Tolerab
 ility of Maridebart Cafraglutide (MARITIME-2-EXTENSION)\nEstimated primary
  completion: 26 December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/maridebart-cafraglutide#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07684144
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684235-143@assetmemo.bio
DTSTAMP:20261121T005422Z
DTSTART;VALUE=DATE:20271226
DTEND;VALUE=DATE:20271227
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT076842
 35)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Extension Trial to Evaluate the Long-term Efficacy\, Safety\, and Tolerab
 ility of Maridebart Cafraglutide (MARITIME-1-EXTENSION)\nEstimated primary
  completion: 26 December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/maridebart-cafraglutide#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07684235
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07575399-143@assetmemo.bio
DTSTAMP:20261121T005422Z
DTSTART;VALUE=DATE:20280103
DTEND;VALUE=DATE:20280104
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT075753
 99)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Efficacy\, Safety and Tolerability of Switching From Glucagon-like Peptid
 e-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With 
 Obesity or Overweight (MARITIME-SWITCH)\nEstimated primary completion: 3 J
 anuary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/marideba
 rt-cafraglutide#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07575399
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07037433-143@assetmemo.bio
DTSTAMP:20261121T005422Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT070374
 33)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcom
 es in Participants With Atherosclerotic Cardiovascular Disease and Overwei
 ght or Obesity\nEstimated primary completion: 30 June 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07037433
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07037459-143@assetmemo.bio
DTSTAMP:20261121T005422Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT070374
 59)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced
  Ejection Fraction and Obesity\nEstimated primary completion: 30 June 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/maridebart-cafraglu
 tide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07037459
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07866066-143@assetmemo.bio
DTSTAMP:20261121T005422Z
DTSTART;VALUE=DATE:20280906
DTEND;VALUE=DATE:20280907
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT078660
 66)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Type 2 Diabetes.
 \nStudy: Maridebart Cafraglutide Versus Semaglutide in Participants With T
 ype 2 Diabetes\nEstimated primary completion: 6 September 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/maridebart-cafraglutide#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07866066
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
